Mersana Therapeutics (MRSN) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Mersana Therapeutics Revenue Highlights


Latest Revenue (Y)

$36.85M

Latest Revenue (Q)

$2.29M

Mersana Therapeutics Revenue by Period


Mersana Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$36.85M38.65%
2022-12-31$26.58M61716.28%
2021-12-31$43.00K-94.81%
2020-12-31$828.00K-98.03%
2019-12-31$42.12M297.61%
2018-12-31$10.59M-39.62%
2017-12-31$17.55M-30.30%
2016-12-31$25.17M142.99%
2015-12-31$10.36M-

Mersana Therapeutics generated $36.85M in revenue during NA 2023, up 38.65% compared to the previous quarter, and up 347.89% compared to the same period a year ago.

Mersana Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$2.29M-75.20%
2024-03-31$9.24M-13.61%
2023-12-31$10.70M39.01%
2023-09-30$7.70M-27.75%
2023-06-30$10.65M36.55%
2023-03-31$7.80M-46.88%
2022-12-31$14.69M163.56%
2022-09-30$5.57M30.09%
2022-06-30$4.28M110.41%
2022-03-31$2.04M18409.09%
2021-12-31$11.00K-
2021-09-30$11.00K-
2021-06-30$11.00K-
2021-03-31$11.00K-
2020-12-31$11.00K-
2020-09-30$11.00K-98.62%
2020-06-30$796.00K7136.36%
2020-03-31$11.00K-73.81%
2019-12-31$42.00K-95.02%
2019-09-30$844.00K317.82%
2019-06-30$202.00K-99.51%
2019-03-31$41.03M3354.12%
2018-12-31$1.19M-44.77%
2018-09-30$2.15M-48.68%
2018-06-30$4.19M36.78%
2018-03-31$3.06M-6.04%
2017-12-31$3.26M-47.97%
2017-09-30$6.27M68.15%
2017-06-30$3.73M-13.12%
2017-03-31$4.29M-64.24%
2016-12-31$12.00M267.75%
2016-09-30$3.26M-47.51%
2016-06-30$6.21M68.11%
2016-03-31$3.70M-

Mersana Therapeutics generated $2.29M in revenue during Q2 2024, up -75.20% compared to the previous quarter, and up 29.39% compared to the same period a year ago.

Mersana Therapeutics Revenue Breakdown


Mersana Therapeutics Revenue Breakdown by Product

Quarterly Revenue by Product

Product/ServiceJun 24
Performance Obligations$1.80M

Mersana Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Performance Obligations (100.00%).

Mersana Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
AMLXAmylyx Pharmaceuticals$380.79M$88.64M
RCUSArcus Biosciences$117.00M$39.00M
PTGXProtagonist Therapeutics$60.00M$4.17M
MRUSMerus$43.95M$11.77M
MRSNMersana Therapeutics$36.85M$2.29M
RLAYRelay Therapeutics$25.55M-
HOOKHOOKIPA Pharma$20.13M-
RVMDRevolution Medicines, Inc. Warrant$11.58M-
PLRXPliant Therapeutics$1.58M-
VRDNViridian Therapeutics$314.00K$72.00K
CGEMCullinan Oncology--
XFORX4 Pharmaceuticals-$563.00K
DAWNDay One Biopharmaceuticals-$20.07M
ABOSAcumen Pharmaceuticals--
INZYInozyme Pharma--
CERECerevel Therapeutics--
REPLReplimune Group--
KURAKura Oncology--
SNDXSyndax Pharmaceuticals-$3.50M
TERNTerns Pharmaceuticals--

MRSN Revenue FAQ


Mersana Therapeutics's yearly revenue for 2023 was $36.86M, representing an increase of 38.65% compared to 2022. The company's yearly revenue for 2022 was $26.58M, representing an increase of 61716.28% compared to 2021. MRSN's yearly revenue for 2021 was $43K, representing a decrease of -94.81% compared to 2020.

Mersana Therapeutics's quarterly revenue for Q2 2024 was $2.29M, a -75.20% decrease from the previous quarter (Q1 2024), and a -78.48% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $9.24M, a -13.61% decrease from the previous quarter (Q4 2023), and a 18.50% increase year-over-year (Q1 2023). MRSN's quarterly revenue for Q4 2023 was $10.7M, a 39.01% increase from the previous quarter (Q3 2023), and a -27.14% decrease year-over-year (Q4 2022).

Mersana Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 85609.30%, and for the last 5 years (2019-2023) was -12.51%.